Drugs / Decitabine and Cedazuridine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07012044 | Jun 2026 → Mar 2027 expected | therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine and Cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07012044 ↗ |
| Route | Oral | “ASTX727 orally (PO) QD on days 2-6” NCT07012044 ↗ |